water extract and platycodin-D are potent hypoglycemic and hypolipemic agents. In the present study, anti-obesity effects of these agents were investigated in various proportions.
Prior to the initiation of dosing, / mice showed marked obesity compared to mice (normal littermates), together with severe hyperglycemia. Epididymal fat weight, serum leptin and liver triglycerides were significantly increased in obese versus intact controls (p<0.01), with significant decrease in serum adiponectin and adipose adiponectin content also seen in the latter group (p<0.01). However, these obesity-related changes were significantly decreased by treatment with . w a t e r e x t r a c t a l o n e o r platycodin-D alone, as well as in combination at all of the tested ratios and more favorable effects were detected in some of the mixed formula groups compared to those of .
water extract alone and platycodin-D alone. Among the 11 mixed formulas, .
water extract: platycodin-D at a ratio of 1:4 showed the most dramatic obesity-inhibiting effects.
Based on the results of this study, it can be concluded that appropriate mixtures of . water extract and platycodin-D exert s u b s t a n t i a l , s y n e r g i c antiobesity effects in obese diabetic mice.
Appropriate MC PLcombination exerted synergistic obesity inhibiting effect in obese diabetic mice
: -

MC:PL combination ratios
Orally administrated once a day for 28 days 
Biomarkers Results
Momordica charantia Linn Water extracts (MC)
and mice, 15 groups n = 7 per group Body weight, Blood glucose, epididymal fat weight, serum leptin, adiponectin, adipose adiponectin and liver triglycerides Significant increase in epididymal fat weight, serum leptin and liver triglycerides, (p<0.01) ignificant decrease in serum adiponectin and adipose adiponectin (p<0.01) MC : PL ratio (1:4) sowed most dramatic obesity-inhibiting effect db/m db/db
Introduction
Recently, there has been a global increase in the incidence of obesity associated with type 2 diabetes, the development of which appears to result from a high-calorie diet intake coupled with physical inactivity (James ., 2001) . It is projected that the incidence of diabetes-related obesity will double to over 300 million cases by 2025 (Zimmet, 2003 . Vigorous efforts have been directed toward delineating the relationship between increased adiposity and insulin resistance. Adipokines (Mitchell ., 2005) , including leptin (Wolf ., 2002) and adiponectin (Yamauchi ., 2003) , are secreted by adipocytes and may modulate insulin sensitivity. In turn, insulin sensitivity in type 2 diabetes is associated with multiple signaling events, following phosphorylation of insulin receptors and several other molecules (Sakaue ., 2003) .
The mouse is hyperleptinemic and thus develops obesity and severe type 2 diabetes, partly due to a functional defect in the long-form leptin receptor (Ob-Rb); this receptor plays a significant role in regulating food intake and controlling body weight (Sharma ., 2003) . Therefore, the genetically obese mouse has been used in field tests of various pharmaceuticals, including anti-type II diabetes and -obesity agents (Neary ., 2005) . Generally, the antiobesity effects of test agents have been evaluated according to their effects on body weight, fat weight and organ and serum lipid profiles (including various adipokines, such as leptin and adiponectin) (Mitchell ., 2005) .
(family Cucurbitaceae), more commonly known as bitter melon, bitter gourd, karela or balsam pear, is a popular vegetable that is grown widely in tropical areas. In addition to culinary usage, it is also used in folklore medicine. Although .
water extract has been found to possess antiviral, antibacterial, anti-HIV, anticancer and immunomodulatory properties, attention has typically been focused on its blood glucose-lowering effect (Basch ., 2003; Efird ., 2014) . This effect was demonstrated in streptozotocininduced diabetic rats (Ahmed ., 2004) and diet-induced obese rats (Chen ., 2003) . In addition, . water extract has shown promising effects for both preventing and delaying the progression of diabetic complications (e.g., nephropathy, neuropathy, gastroparesis, cataract and insulin resistance) in experimental animals (Rathi ., 2002) , in turn mediated by the insulin-like activity of polypeptide-p (phytoinsulin) as well as enhanced pancreatic beta cell of charantin expression and glucose utilization (Sarkar ., 1996) . Freezedried .
juice feeding leads to a general decrease in accumulated tissue fat and blood glucose, effects that are in part mediated by enhanced sympathetic activity and lipolysis in rats (Chen and Li, 2005 (Chen and Li, 2005) . Park and Heo (2011) found that bitter melon ( ) extracts had beneficial effects on body weight change and lipid composition in C57/BL6J mice fed with high-fat diet. Recently, the beneficial role of bitter melon supplementation in addressing obesity and related complications in metabolic syndrome was observed (Alam ., 2015) .
Platycodi radix, the root of , has been used traditionally as an expectorant and remedy for bronchitis, tonsillitis, laryngitis and suppurative dermatitis in Korea, China and Japan. In China and Korea, the fresh roots of are eaten in pickled form to prevent obesity (Han ., 2000) . It has been reported that platycodin-D, a major component of Platycodi radix (Han ., 2002) , shows antiobesity, -diabetes and -hypolipemia effects (Han ., 2000 (Han ., , 2002 , evidenced by improved insulin resistance in obese Zucker rats (Kim ., 2000) . However, the effective dose against obesity was much higher than the ideal dosage of an antiobesity agent: 0.5 g l and at least 244 mg kg in animals (Han ., 2000) .
A number of oral anti-diabetic medicines are currently in use, or are in development, including thiazolidinedione (TZD) and metformin, both of which improve insulin resistance. Metformin inhibits hepatic glucose production via reduced gluconeogenesis (Seufert ., 2004) , and effectively inhibits high fat diet-induced obesity in mice (Park ., 2005) . However, currently available pharmacological agents for the treatment of diabetes and diabetes-related obesity have numerous limitations, including various adverse effects and high rates of secondary failure (Inzucchi, 2002) . Therefore, diabetic patients and healthcare professionals are interested in complementary, alternative approaches, including the use of medicinal herbs. However, it is very difficult to develop antiobesity agents using such herbs because they have relatively high efficacy dosages in animal experiments and human clinical trials.
In this study, the complementary and alternative treatment for obesity by mixing two potent hypoglycemic and hypolipemic agents: .
water extract and platycodin-D was further explored. To ascertain the optimal ratio, the antiobesity effects of eleven .
water extract + platycodin-D mixtures were assessed in obese mice at 200 mg kg . Test agents were administered orally once a day for 28 days and changes in body weight, epididymal fat weight, blood glucose, serum leptin, adiponectin, fat adiponectin and liver triglycerides were measured.
: In total, 196, genetically obese male mice with C57BL/KsJ genetic background and 14 lean nondiabetic heterozygous littermates ( mice, seven weeks of age; Clear Japan Co., Tokyo, Japan) were used following 
Materials and Methods
Mice and husbandry
Body weight changes
Estimation of blood glucose of epididymal fat weight of serum adiponectin levels of adiponectin content in epididymal adipose tissue : Changes in body weight were calculated one day before dosing, at initial dosing and after 1, 7, 14, 21, 27 and 28 days using an automatic electronic balance (Sartorius Co., Ltd., Long Island, NY, USA). At both initial dosing and sacrifice, animals were fasted overnight (only water was available for about 12 hrs) to reduce interindividual differences in feeding behavior. Body weight gain was calculated by deducting weight at sacrifice with weight at initial dosing. : To measure blood glucose level, blood was collected one day before initial dosing, and after 28 days of dosing from the orbital plexus.
Collected blood was deposited into a NaF glucose vacuum tube (Becton Dickinson, Franklin Lakes, NJ, USA) and plasma was separated. Blood glucose levels were detected using an automated blood analyzer (Toshiba 200 FR, Tokyo, Japan). In addition, changes in blood glucose level between initial dosing and after 28 days were calculated by deducting blood level at initial dosing with blood level at sacrifice.
: The animals were sacrificed by administering CO gas in an anesthetizing box (the 7900 induction box, Ugo Basile S. R. L., Gemonio, VA, Italy) according to the method developed by Danneman . (1997). After sacrifice, epididymal adipose tissue was removed and weighed to reduce error. The relative percentage of fat weight was calculated by dividing absolute epididymal fat weight the body weight at sacrifice.
: To measure serum adiponectin levels, blood was collected at sacrifice from the vena cava after overnight fasting. To separate the serum from the blood, one milli litre sample of venous blood was collected from the vena cava under anesthesia using CO gas. All blood samples in a clotting activated serum tube were centrifuged at 600 x g for 10 min at room temperature using a centrifuge (Thermo Scientific Sorvall Legend Mach 1.6R; Thermo Fisher Scientific, Inc., Waltham, MA, USA). Serum adiponectin levels were detected using a commercially available ELISA kit (Otsuka Co., Ltd., Tokushima, Japan).
: Adipose tissue adiponectin content was determined by Western blot analysis, as described previously (Fujita ., 2005) . The removed epididymal adipose tissue was homogenized in PBS containing 0.5% sodium deoxycholate. Homogenates were incubated for 24 hrs at 37°C. After incubation, the homogenates were centrifuged at 15,000 g for 10 min. The fat cake was removed by suction and adipose tissue extracts (supernatants) were used for Western blot analysis. Aliquots of the tissue extracts ( 10 μg protein) prepared in sodium dodecyl sulfate (SDS) sample buffer were incubated for 5 min at 100°C. Denatured proteins were separated by sodium dodecyl acclimatization for seven days. Animals were allocated to polycarbonate cages (n = 7 per cage) in a temperature (20-25ºC) and humidity (40-45%) controlled room. The light:dark cycle was 12:12 hrs, and standard rodent chow (Samyang, Masan Korea) and water were supplied ad libitum.About half of the animals were selected (seven per group) for the estimation of fasting blood glucose levels and body weight at one day before dosing commenced. The mean fasting blood glucose level in mice one day before initial dosing was 102.43 ± 10.86 mg dl , compared to 276.53 ± 9.17 mg dl in mice. Animal care and use was in accordance with the guidelines of our institution and the protocol was approved by the Institutional Animal Care and Use Committee of Silla University (Busan, Korea; approval no. SUACUC-2016-008).
: and Platycodi radix used in this study were purchased from Bonchowon (Seoul, Korea). Briefly, dried . fruit (containing seeds) was ground using a commercial electronic pulverizer. Approximately, 200 g of lyophilized MC water extract was prepared from 1,500 g of ground .
and evaporated in 15 l of water for 12 hrs in a commercial rotary vacuum evaporator at 105ºC (LAB Camp, Daejeon, Korea). The extract was then kept in a programmable freeze dryer (IlShin Lab., Yangju, Korea). The raw sample (100 kg) of Platycodi radix was extracted with methanol and partitioned sequentially with nhexane, chloroform, ethyl acetate and n-butanol. The n-butanol fraction was then subjected to a Diaion HP-20 resin (Mitsubishi Chemical Corp., Tokyo, Japan), and the fractions eluted at 60-80% of methanol were collected to obtain 90 g of crude saponins. The crude saponins were further purified by repeated silica gel (Merck, Darmstadt, Germany) chromatography to obtain the purified platycodin-D. This process was repeated several times until a sufficient quantity of platycodin-D was obtained. The purified was identified on the basis of the Rf value from a chromatographic analysis, fast atom bombardment-mass spectrometry (FAB-MS) (nominal mass = 1,225.38) and carbon-13 nuclear magnetic resonance (13C-NMR) spectra results and compared with the authentic PL. Purity was assessed based on the high-performance liquid chromatography (HPLC) chromatogram of Zorbax SB-Aq (ODS C18 column; Agilent, Palo Alto, CA, USA) equipped with an evaporative laser scattering detector (Sedex 75; Sedere, Alfortville, France), as described previously (Zhao ., 2006) . The prepared platycodin-D and .
water extract samples were stored in a refrigerator at 4ºC to protect them from light and degeneration. Then, .
water extract, platycodin-D and 11 .
water extract + platycodin-D mixtures were dissolved in distilled water, and animals were dosed by oral gavage using a sonde attached to 3 ml syringes containing test agents (200 mg kg per day for 28 days). The doses, .
water extract + platycodin-D formulations, and dosage schedules are detailed in Table 1 .
Preparation and administration of drugs platycodin-D J.H. Sohn et al.
sulfate-polyacrylamide gel electrophoresis (SDS-PAGE) and then transferred to polyvinylidene difluoride (PVDF) membranes (Bio-Rad, Hercules, CA, USA). The membranes were incubated with a 1:10,000 dilution of mouse anti-mouse adiponectin monoclonal antibody (Chemicon International, Billerica, MA, U Adiponectin protein content per 10 μg of adipose tissue protein, in intact controls and all dose groups, was normalized to that of obese control using the same assay and expressed as a percentage of the control group. μM PMSF. Triglyceride content in the liver homogenates was measured using a spectrophotometry kit (Thermo DMA, Louisville, CO, USA), as described previously (Sahai SA) for 12 hrs at room temperature and then incubated with a 1:5,000 dilution of horseradish peroxidase-conjugated goat antimouse immunoglobulin G (IgG) antibody (DAKO, Carpinteria, CA, USA) for 1 hr at room temperature. After incubation, the membranes were soaked in chemiluminescence solution using electrochemiluminescence (ECL) Western blotting detection reagents (Amersham International, Amersham, UK). The membranes were exposed to X-ray film to visualize the adiponectin protein. Signals from the X-ray film were quantified using a charge-coupled device (CCD) image analyzer system (DMI, Daegu, Korea).
: To detect serum leptin levels, blood was collected after sacrifice from the vena cava after overnight fasting, and serum was separated from collected blood using general methods. Serum leptin levels were detected using a commercially available radioimmunoassay kit (Linco Research, St. Charles, MO, USA), as described previously (Sahai ., 2004) .
: Liver samples (50-70 mg) were homogenized in 50 mM Tris-HCl buffer (pH 7.4) containing 150 mM NaCl, 1 mM EDTA and 1 ., 2004).
: Data were presented as means ± SD (n = 7 per group). The Mann Whitney U-Wilcoxon rank sum W test (MW test) was performed using SPSS for Windows software (ver. 6.1.3.; SPSS Inc., Chicago, IL, USA). Differences between intact and obese control were evaluated. To gauge the effectiveness of the test agents, inhibition in all dosing groups compared to that of obese control. The percentage changes are compared to intact control by subtracting the intact control from obese control and then dividing the sum of all intact control. The percentage changes compared to obese control was calculated by subtracting the obese control from the dosing groups and then dividing the sum of all obese control.
Before initial dosing, mice showed marked obesity compared to mice. Significant increase in body weight were observed throughout the experiment in obese versus intact control (p<0.01) and body weight gain between initial dosing and after 28 days was also significantly greater in obese animals (p<0.01). However, there was significantly less body weight gain between initial dosing and after 28 days in all dosing groups versus obese control (p<0.01 or p<0.05). Body weight significantly decreased after 21 days in 1:4 ratio + platycodin-D group and after 27 days in other groups (including alone and alone) compared to, obese control (p<0.01 or p<0.05; Table 2 and Fig. 1 ).
Significant increase in blood glucose levels (p<0.01) and significant changes between initial dosing and after 28 days were detected in obese versus intact control. However, significant decrease in blood glucose levels, and significant changes after 28 days, were detected in all dosing groups compared to obese control (p<0.01 or p<0.05), except for platycodin-D alone and 1:10 .
water extract + platycodin-D groups, in which non-significant decrease were detected. More dramatic hypoglycemic effects were detected in all the mixed formulation groups relative to single formulation groups, except for 1:8 and 1:10 .
water extract + platycodin-D groups, in which more favorable hypoglycemic effects relative to platycodin-D alone group were detected (Table 3 ). In the obese control, the blood glucose level one day before initiation of dosing was 185.11% higher than in the intact control. 
effects of bitter melon and platycodin-D in obese mice
Significant increase in absolute and relative epididymal adipose tissue weight were detected in obese versus intact control (p<0.01). However, significant decrease in absolute and relative fat weight were detected in all dosing groups compared to obese control (p<0.01 or p<0.05). More dramatic inhibition of fat deposition was seen in all of the mixed formulation groups relative to single formulation groups, with exception of 1:10, 6:1, 8:1 and 10:1 ratios .
water extract + platycodin-D groups, in M charantia which non-significant inhibitory effects were observed relative to . water extract alone group (Table 4 ). In the obese control, absolute epididymal adipose tissue weight was 908.49% higher than in the intact control.
A significant decrease in serum adiponectin level was detected in the obese versus intact control (p<0.01). However, a significant increase in serum adiponectin level was detected in all M charantia 
Values are mean of seven replicates ±SD ; Single formulation; Mixed formulation; Relative liver weight (%) = ((Absolute organ weight / Body weight at sacrifice) × 100); * p<0.01 compared to that of intact control by MW test; p<0.01 and p<0.05 compared to that of obese control by MW test
# ##
Values are mean of seven replicates ±SD dosing groups compared to the obese control group (p<0.01). More dramatic inhibition of decreased serum adiponectin levels was seen in all mixed formulation groups compared to single formulation groups, except for . water extract + platycodin-D in 8:1 and 10:1 ratios, in which non-significant beneficial inhibitory effects were observed compared to .
water extract alone (Table 5) . In obese control, the serum adiponectin level was 49.45% lower than in the intact control.
M charantia M charantia
A significant decrease in epididymal adipose tissue adiponectin content was detected in the obese versus intact control (p<0.01). However, a significant increase in epididymal adipose tissue adiponectin content was detected in all dosing groups compared to the obese control (p<0.01). More dramatic inhibition of fat adiponectin was detected in all mixed formulation groups compared to the single formulation groups, except for .
water extract + platycodin-D in 8:1 and 10:1 ratios, in
M charantia Inhibitory effects of bitter melon and platycodin-D in obese mice
which non-significant beneficial inhibitory effects were observed compared to .
water extract alone (Table 5 ). In the obese control group, the epididymal adipose tissue adiponectin content was 62.53% lower than in the intact control group. Asignificant increase in serum leptin level was detected in the obese versus intact control (p<0.01). However, a significant decrease in serum leptin level was detected in all dosing groups compared to that of the obese control (p<0.01 or p<0.05). More dramatic inhibition of serum leptin was detected in all mixed formulation groups compared to the single formulation groups, except for .
water extract + platycodin-D in 6:1, 8:1 and 10:1 ratios, in which non-significant beneficial inhibitory effects were observed compared to .
water extract alone (Table 5) . In obese control, the serum leptin level was 533.49% higher than in the intact control.
A significant increase in liver triglycerides was detected in the intact control group compared to group (p<0.01). However, a significant decrease in liver triglycerides was detected in all dosing groups compared to obese control (p<0.01). A more dramatic inhibition of increased liver triglycerides was detected in all mixed formulation groups compared to the single formulation groups, except for .
water extract + platycodin-D in 8:1 and 10:1 ratios, in which non-significant beneficial inhibitory effects were observed compared to .
water extract alone (Table 5) . In obese control, the liver triglyceride level was 53.27% higher than in the intact control. 
M charantia
In the present study, the complementary and alternative treatments for obesity further investigated by mixing two potent hypoglycemic and hypolipemic agents: .
water extract and . Bitter melon ( L.) is widely used for the treatment of diabetes. It has been shown that can increase the number of beta cells (Ahmed ., 1998). In another study, .
acted like insulin and also promoted insulin release (Higashino ., 1992) . Some studies have also attributed hypoglycemic activity to an extra-pancreatic effect (Sarkar ., 1996) , including increased expression of GLUT4 transporter protein in muscles (Miura ., 2004) , increased glucose utilization in liver and muscles (Sarkar ., 1996) , inhibition of glucose-6-phosphatase and fructose-1, 6-bisphosphatase in liver, and stimulation of red-cell and hepatic glucose-6-phosphate dehydrogenase activity (Shibib ., 1993) .
Recent research reports suggest that bitter melon extracts may ameliorate high-fat-diet-induced obesity and hyperlipidemia in animal models (Alam ., 2015) . Melon extracts have beneficial effects on body weight gain and abdominal fat deposition, early signs of obesity (Alam ., 2015) . Several reports suggest that bitter melon can reduce body weight in -diet-induced obesity in laboratory animals and bitter melon (0.75% of diet) supplementation showed a significant positive effect on the body weight gain and visceral fat mass in rats fed with diet (Chen and Li, 2005) . This weightreduction effect may be a result of increased fatty acid oxidation, high-fat high-fat . (2011) reported that 2 ml per day of aqueous extract of bitter melon significantly reduced body weight gain in rats. A recent study also showed that supplementation with seed oil of bitter melon reduced body weight and fat mass in mice fed with diet (Chen ., 2012).
Approximately, 228 different compounds that have possible medicinal properties by themselves or in combination have been isolated from bitter melon fruit, seeds, leaves, stems, pericaps, endosperm, callus tissues and cotyledons (Singh ., 2011) . These materials contain hundreds of chemical compounds such as saponins, polysaccharides, proteins, triterpenoids, alkaloids, flavonoids, quinine, amino acids, fatty acids and trace elements (Zhang ., 2016) . Depending on the characteristics of the compounds isolated from .
, they can be divided into several groups (e.g., phenolic and flavonoid compounds, cucurbitane-type triterpenoids, cucurbitane-type triterpene glycoside, oleanane-type triterpene saponins and insulin-like peptides) (Alam ., 2015; Efird ., 2014) . Their beneficial effects on health have been partly attributed to these bioactive components of . (Zhang ., 2016; Alam ., 2015; Efird ., 2014) .
The effects of platycodin-D against obesity and hypolipemia have also been studied (Han ., 2000 (Han ., , 2002 and it is generally accepted that the antiobesity activity of platycodin-D is mediated by the inhibition of intestinal absorption of dietary fat (via inhibition of pancreatic lipase activity) (Han ., 2002) . The antiobesity activity of platycodin-D is also associated with inhibition of acyl-coenzyme A (CoA) : cholesterol acyltransferase (ACAT) activity, antagonism of farnesoid X receptor and formation of an insoluble complex between platycodin-D and cholesterol (Zhao ., 2006) .
Although the exact mechanism of action remain unknown, the favorable synergic effects of . water extract and platycodin-D are mediated by various factors, enclosing insulin-like activity, increased pancreatic beta cell expression, sympathetic activity and lipolysis, inhibition of the intestinal absorption of fats (via inhibition of pancreatic lipase), inhibition of hACAT activity, antagonism of farnesoid X receptor and formation of an insoluble complex.
